Showing results (191-200 of 214) with videos related to
Sort By:
Pageof 22
International Journal of Cancer|May 4, 2023
KEYNOTE-033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLCShengxiang Ren, Jifeng Feng, Shenglin Ma, et al.International Journal of Radiation Oncology, Biology, Physics|November 21, 2020
Erlotinib Versus Etoposide/Cisplatin With Radiation Therapy in Unresectable Stage III Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Phase 2 TrialLigang Xing, Gang Wu, Luhua Wang, et al.Aging|March 13, 2021
A COVID-19 risk score combining chest CT radiomics and clinical characteristics to differentiate COVID-19 pneumonia from other viral pneumoniasZuhua Chen, Xiadong Li, Jiawei Li, et al.Cell Metabolism|May 24, 2015
GDF11 Increases with Age and Inhibits Skeletal Muscle RegenerationMarc A Egerman, Samuel M Cadena, Jason A Gilbert, et al.Nature Medicine|June 21, 2022
Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a studyStephen A Harrison, Federico Perez Manghi, William B Smith, et al.Liver International : Official Journal of the International Association for the Study of the Liver|July 14, 2023
Non-invasive candidate protein signature predicts hepatic venous pressure gradient reduction in cirrhotic patients after sustained virologic responseShola M Richards, Fang Guo, Heng Zou, et al.Journal of Hematology & Oncology|May 18, 2022
Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patientsZhen Zhou, Zhengping Ding, Jie Yuan, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 10, 2025
First-Line Camrelizumab Versus Placebo Plus Chemotherapy With or Without Radiotherapy for Brain Metastases in NSCLC: The CTONG 2003 Randomized Placebo-Controlled TrialYang-Si Li, Qitao Yu, Qing Bu, et al.Med (New York, N.Y.)|April 12, 2025
Multidisciplinary expert consensus on diagnosis and treatment of multiple lung cancersKezhong Chen, Anwen Liu, Changli Wang, et al.Translational Lung Cancer Research|February 4, 2020
Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancerYunpeng Yang, Bin Wu, Linian Huang, et al.Pageof 22